Back to media

SEED AACR 2026 Presentation: RBM39 Degrader Anticancer Activity Against Neuroblastoma; MYC and CDKN2A/B as Potential Response Biomarkers

Publications
April 30, 2026
info@seedtherapeutics.com
411 Swedeland Rd, Suite 1000,
King of Prussia, PA, 19406
HomeTeamOur PipelineMediaOur ScienceContactReferences
© 2026 Seed Therapeutics. All rights reserved.
Privacy PolicyTerms & ConditionsSite by Bunsen